Akebia Therapeutics Inc.

AKBAUnited States

30 filed reports · 505 financial concepts · 12 earnings calls

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$236M

FY2025 · to Dec 31, 2025

up +47.5% vs $160M

10-K

Net income

-$5.35M

FY2025 · to Dec 31, 2025

a year earlier: -$69.4M

10-K

Operating income

$23.5M

FY2025 · to Dec 31, 2025

a year earlier: -$50.5M

10-K

Latest quarter

Revenue

$36.9M

Q3 FY2026 · to Sep 30, 2026

down −37.2% vs $58.8M

10-Q

Net income

-$14.4M

Q3 FY2026 · to Sep 30, 2026

a year earlier: $540K

10-Q

Operating income

-$11.5M

Q3 FY2026 · to Sep 30, 2026

a year earlier: $4.45M

10-Q

Filed reports

30 reports · Dec 2019 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 earnings-release figures, 37 commentary passages.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR214,158Mar 2020 to Sep 2026
Annual · 10-KSEC EDGAR73,090Dec 2019 to Dec 2025
Annual · 10-K/ASEC EDGAR1713Dec 2022
Current · 8-KSEC EDGAR12Sep 2026

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q38-K2026-09-302026-11-052Open
FY2026 Q310-Q2026-09-302026-11-05489Open
FY2026 Q210-Q2026-06-302026-08-05283Open
FY2026 Q110-Q2026-03-312026-05-07270Open
FY202510-K2025-12-312026-02-26985Open
FY2025 Q310-Q2025-09-302025-11-10224Open
FY2025 Q210-Q2025-06-302025-08-07200Open
FY2025 Q110-Q2025-03-312025-05-08203Open
FY202410-K2024-12-312025-03-13267Open
FY2024 Q310-Q2024-09-302024-11-07189Open
FY2024 Q210-Q2024-06-302024-08-08182Open
FY2024 Q110-Q2024-03-312024-05-09177Open

Financial data

505 concepts · 7,963 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial481 concepts · 7,590 facts · Dec 2017 to Sep 2026

  • Net income loss44 · Dec 2017 to Sep 2026
  • Operating expenses (US GAAP)44 · Dec 2017 to Sep 2026
  • Operating income loss44 · Dec 2017 to Sep 2026
  • Cash and cash equivalents at carrying value42 · Dec 2017 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents42 · Dec 2017 to Sep 2026
  • Stockholders equity (US GAAP)42 · Dec 2017 to Sep 2026
  • Valuation allowances and reserves balance41 · Dec 2018 to Sep 2026
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value40 · Dec 2017 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect40 · Dec 2017 to Sep 2026
  • Comprehensive income net of tax40 · Dec 2017 to Sep 2026
  • Contract with customer liability revenue recognized40 · Dec 2017 to Sep 2026
  • Cost of revenue (US GAAP)40 · Dec 2018 to Sep 2026
  • Increase decrease in accounts payable40 · Dec 2017 to Sep 2026
  • Increase decrease in accounts receivable40 · Dec 2017 to Sep 2026
  • Increase decrease in accrued liabilities40 · Dec 2017 to Sep 2026
  • Increase decrease in contract with customer liability40 · Dec 2017 to Sep 2026
  • Increase decrease in other noncurrent assets40 · Dec 2017 to Sep 2026
  • Increase decrease in prepaid deferred expense and other assets40 · Dec 2017 to Sep 2026
  • Interest income expense nonoperating net40 · Dec 2017 to Sep 2026
  • Net cash provided by used in financing activities40 · Dec 2017 to Sep 2026
  • Net cash provided by used in investing activities40 · Dec 2017 to Sep 2026
  • Net cash provided by used in operating activities40 · Dec 2017 to Sep 2026
  • Other nonoperating income expense40 · Dec 2017 to Sep 2026
  • Payments to acquire property plant and equipment40 · Dec 2017 to Sep 2026

Segment18 concepts · 226 facts · Dec 2023 to Sep 2026

  • Direct cost of product and other revenue14 · Dec 2023 to Sep 2026
  • Fair value adjustment of warrants14 · Dec 2023 to Sep 2026
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest14 · Dec 2023 to Sep 2026
  • Interest income expense nonoperating net14 · Dec 2023 to Sep 2026
  • License14 · Dec 2023 to Sep 2026
  • Net income loss14 · Dec 2023 to Sep 2026
  • Operating income loss14 · Dec 2023 to Sep 2026
  • Other nonoperating income expense14 · Dec 2023 to Sep 2026
  • Research and development expense14 · Dec 2023 to Sep 2026
  • Restructuring charges14 · Dec 2023 to Sep 2026
  • Revenue14 · Dec 2023 to Sep 2026
  • Royalty expense14 · Dec 2023 to Sep 2026
  • Selling general and administrative expense14 · Dec 2023 to Sep 2026
  • Income tax expense benefit12 · Dec 2023 to Sep 2026
  • Amortization of intangible assets11 · Dec 2023 to Dec 2025
  • Gains losses on extinguishment of debt11 · Dec 2023 to Dec 2025
  • Long term purchase commitment amount7 · Dec 2023 to Dec 2025
  • Gain loss on termination of lease3 · Dec 2023 to Dec 2025

Product5 concepts · 145 facts · Dec 2017 to Sep 2026

  • Revenue118 · Dec 2017 to Sep 2026
  • Contract with customer liability revenue recognized12 · Mar 2024 to Sep 2026
  • Additions7 · Sep 2025 to Sep 2026
  • Deductions7 · Sep 2025 to Sep 2026
  • Revenue From Contract With Customer, Excluding Assessed Tax, Potential Royalty Percentage1 · Jun 2020

KPI1 concept · 2 facts · Dec 2025 to Sep 2026

  • Working capital2 · Dec 2025 to Sep 2026

Segments

371 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments1 member · 226 facts

  • Reportable226 · Dec 2023 to Sep 2026

Product or service9 members · 145 facts

  • License Collaboration And Other Revenue44 · Dec 2017 to Sep 2026
  • Product40 · Dec 2018 to Sep 2026
  • Auryxia14 · Dec 2023 to Sep 2026
  • Sales To AG Distributor14 · Mar 2025 to Sep 2026
  • Vafseo14 · Dec 2023 to Sep 2026
  • License And Other Revenue6 · Sep 2025 to Sep 2026
  • License Collaboration And Other Revenue Royalties6 · Mar 2025 to Sep 2026
  • Sales To AG Partner6 · Mar 2024 to Sep 2025
  • VAFSEO1 · Jun 2020

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary12 claims from 1 report · Sep 2026
  • Management discussion (MD&A) commentary25 claims from 1 report · Sep 2026

Earnings calls

12 calls · May 2023 to Nov 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-11-05
  • FY2026 Q12026-05-07
  • FY2025 Q42026-02-26
  • FY2025 Q32025-11-10
  • FY2025 Q22025-08-07
  • FY2025 Q12025-05-08
  • FY2024 Q42025-03-13
  • FY2024 Q32024-11-07
  • FY2024 Q12024-05-09
  • FY2023 Q32023-11-08
  • FY2023 Q22023-08-25
  • FY2023 Q12023-05-08

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Akebia Therapeutics Inc. (AKBA) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.